Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 7.41
ANAB's Cash-to-Debt is ranked lower than
58% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. ANAB: 7.41 )
Ranked among companies with meaningful Cash-to-Debt only.
ANAB' s Cash-to-Debt Range Over the Past 10 Years
Min: 3.49  Med: 10.11 Max: N/A
Current: 7.41
Equity-to-Asset -0.62
ANAB's Equity-to-Asset is ranked lower than
96% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ANAB: -0.62 )
Ranked among companies with meaningful Equity-to-Asset only.
ANAB' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.39  Med: -0.62 Max: 0.8
Current: -0.62
-1.39
0.8
Altman Z-Score: 15.17
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -71.17
ANAB's Operating Margin % is ranked higher than
53% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. ANAB: -71.17 )
Ranked among companies with meaningful Operating Margin % only.
ANAB' s Operating Margin % Range Over the Past 10 Years
Min: -96.43  Med: -18.52 Max: 30.75
Current: -71.17
-96.43
30.75
Net Margin % -88.74
ANAB's Net Margin % is ranked lower than
51% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. ANAB: -88.74 )
Ranked among companies with meaningful Net Margin % only.
ANAB' s Net Margin % Range Over the Past 10 Years
Min: -101.13  Med: -28.15 Max: 22.3
Current: -88.74
-101.13
22.3
ROE % -166.65
ANAB's ROE % is ranked lower than
88% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. ANAB: -166.65 )
Ranked among companies with meaningful ROE % only.
ANAB' s ROE % Range Over the Past 10 Years
Min: -166.65  Med: 0 Max: 0
Current: -166.65
-166.65
0
ROA % -20.43
ANAB's ROA % is ranked higher than
58% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. ANAB: -20.43 )
Ranked among companies with meaningful ROA % only.
ANAB' s ROA % Range Over the Past 10 Years
Min: -141.67  Med: -10.24 Max: 24.38
Current: -20.43
-141.67
24.38
ROC (Joel Greenblatt) % -1870.34
ANAB's ROC (Joel Greenblatt) % is ranked lower than
69% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. ANAB: -1870.34 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ANAB' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1870.34  Med: -476.59 Max: 724.3
Current: -1870.34
-1870.34
724.3
GuruFocus has detected 1 Warning Sign with AnaptysBio Inc $ANAB.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ANAB's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with NAS:ANAB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:DVAX, NAS:ITCI, NAS:ANIP, NAS:CCXI, NAS:NK, NAS:RXDX, NAS:CARA, NAS:BOLD, NAS:OTIC, NAS:CTMX, NAS:PGNX, NAS:ALDR, NAS:VSAR, NAS:INO, NAS:BCRX, NAS:SPPI, NAS:IMGN, NAS:GERN, NAS:MCRB, NAS:RGNX » details
Headquarter Location:USA
AnaptysBio Inc is a biotechnology company. The Company is engaged in developing first-in-class antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. Its product include ANB020 and ANB019.

AnaptysBio Inc was incorporated under the laws of the State of Delaware on November 17, 2005. The Company is a biotechnology company engaged in developing first-in-class antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using proprietary antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. The Company's platform is based upon a breakthrough understanding of somatic hypermutation, the key biological process utilized to generate antibodies, which enables to develop functional antibody drug candidates against emerging biological targets. The Company's programs, ANB020 and ANB019, are being developed to treat severe inflammatory disorders with unmet medical need. The Company's ANB020 product is an antibody that inhibits the activity of interleukin-33, or IL-33, a pro-inflammatory cytokine that multiple studies have indicated is a central mediator of atopic diseases, including asthma, food allergies and atopic dermatitis. Its ANB019 product is an antibody that inhibits the function of the interleukin-36-receptor, or IL-36R, which are initially developing as a potential first-in-class therapy for GPP patients. The Company faces competition from major pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions. The Company's competitors include Xolair, Roche, Glaxosmithkline, Teva, AstraZeneca, and Pfizer. In the United States, pharmaceutical products are subject to extensive regulation by the FDA.

Top Ranked Articles about AnaptysBio Inc

AnaptysBio to Participate in Upcoming Investor Conferences
AnaptysBio Announces First Quarter 2017 Financial Results and Provides Pipeline Update
AnaptysBio Announces First-In-Human Dosing of ANB019
AnaptysBio Announces 2016 Operating Results and Pipeline Progress

Data from Ongoing ANB020 Phase 2a Trials and ANB019 Phase 1 Trial Expected in Second Half 2017

SAN DIEGO, March 08, 2017 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced progress on the Company’s product pipeline, business highlights and reported full year 2016 financial results.
“We are pleased to have advanced our novel anti-IL-33 antibody, ANB020, through Phase 1 during 2016 and cleared both US and UK regulatory filings to enable multiple Phase 2 clinical data readouts in the second half of 2017,” said Hamza Suria, president and chief executive officer of AnaptysBio. “With the success of our recently completed initial public offering, AnaptysBio is well-positioned to execute our strategy of developing novel antibody approaches to treat severe inflammatory disease.” Pipeline and Business Highlights  
ANB020 (Anti-IL-33 Program) Phase 1 Data Presented and Multiple Phase 2a Clinical Trials Enrolling AnaptysBio completed a double-blind, placebo-controlled Phase 1 clinical trial of ANB020, which demonstrated that ANB020 was well-tolerated and no dose-limiting toxicities were observed at any dose level. An ex vivo pharmacodynamic assay illustrated that a single dose of ANB020 at certain dose levels was sufficient to suppress IL-33 function for approximately three months post-dosing. Detailed data from this Phase 1 clinical trial was presented at the 2017 American Academy of Dermatology (AAD) Annual Meeting on March 3, 2017 and the American Academy of Allergy, Asthma and Immunology (AAAAI) 2017 Annual Meeting on March 4, 2017.AnaptysBio initiated a Phase 2a clinical trial for ANB020 in adult patients with severe peanut allergy, a condition that can result in systemic life-threatening anaphylaxis. Patient enrollment is ongoing in the U.S. and top-line results from this trial are anticipated during the second half of 2017.AnaptysBio initiated a Phase 2a clinical trial for ANB020 for the treatment of adults with moderate-to-severe atopic dermatitis, a challenging type of allergic skin inflammation. Patient enrollment is ongoing in the U.K. and top-line results from this trial are anticipated during the second half of 2017.Scientific collaborators at the Benaroya Research Institute presented a translational research study regarding the potential role of IL-33 in severe peanut allergy at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2017 Annual Meeting on March 4, 2017. The research concluded that IL-33 is a key checkpoint of allergic responses, and blocking IL-33 has the potential to reduce expression of the effector cytokines involved in severe peanut allergy. ANB019 (Anti-IL-36 Receptor Program) Phase 1 Clinical Data Anticipated in second half 2017 AnaptysBio is planning to initiate a Phase 1 clinical trial in healthy volunteers in Australia in which ANB019 will be administered in single and multiple doses through subcutaneous and intravenous routes of administration, with top-line results expected during the second half of 2017. Phase 2 studies for the treatment of two orphan inflammatory diseases, generalized pustular psoriasis and palmo-plantar pustular psoriasis, are anticipated to begin during 2018. Checkpoint Receptor Agonist Antibodies Demonstrate Efficacy in Preclinical Model AnaptysBio has developed a portfolio of novel checkpoint receptors agonist antibodies designed to treat autoimmune diseases that have recently demonstrated efficacy in a rodent model of graft-versus-host disease. By agonizing checkpoint receptors expressed on immune cells associated with autoimmune disease, these antibodies are anticipated to preferentially suppress disease-causing, auto-reactive immune cells, which the Company believes would reduce their potential to cause broad immunosuppression in patients. The Company plans to advance a checkpoint agonist antibody to the clinic in 2019. Partnerships Advance Three AnaptysBio-Generated Antibodies into Clinical Trials Under an immuno-oncology partnership with AnaptysBio, TESARO is advancing a Phase 1 clinical study of an AnaptysBio-generated anti-PD-1 antagonist antibody (TSR-042). AnaptysBio anticipates initiation of a registration program for TSR-042 by TESARO during the first half of 2017.A second Phase 1 trial is underway by TESARO studying an AnaptysBio-generated anti-TIM-3 antagonist antibody (TSR-022), and a combination trial of TSR-022 with an anti-PD-1 antibody is expected to be initiated in mid-2017.A third Phase 1 trial is expected to be initiated by TESARO for an AnaptysBio-generated anti-LAG-3 antagonist antibody (TSR-033) in the second quarter of 2017.Under an inflammation partnership with Celgene, a Phase 1 trial is underway evaluating an AnaptysBio-generated PD-1 agonist antibody (CC-90006). Initial Public Offering Completed AnaptysBio completed its initial public offering of 5,750,000 shares of its common stock at a public offering price of $15.00 per share in January 2017, which included the exercise in full by the underwriters of their option to purchase an additional 750,000 shares of common stock. Net proceeds generated from the offering were $80.2 million. Full Year 2016 Financial Results and Financial Guidance Cash and cash equivalents totaled $51.2 million as of December 31, 2016, compared to $51.7 million as of December 31, 2015. As of January 31, 2017, cash and cash equivalents totaled $130.2 million and reflects net proceeds of $80.2 million received from the initial public offering, which closed on January 31, 2017. The Company expects that its existing cash and cash equivalents, and projected revenue under its existing collaborations, will fund its anticipated operations through 2018.Research and development expenses were $15.4 million for the year ended December 31, 2016, compared to $17.3 million for the year ended December 31, 2015. The decrease was primarily due to the recognition of certain tax incentives in 2016, offset by an increase in preclinical and clinical trial expenses. General and administrative expenses were $4.3 million for the year ended December 31, 2016, compared to $3.6 million for the year ended December 31, 2015. The increase was attributable to additional personnel-related expenses due to an increase in headcount and an increase in legal expenses. About AnaptysBio
AnaptysBio is a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation. The company’s proprietary anti-inflammatory pipeline includes its anti-IL-33 antibody (ANB020) for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy and severe adult eosinophilic asthma; its anti-IL-36R antibody (ANB019) for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases where immune checkpoint receptors are insufficiently activated and have demonstrated efficacy in an animal model of graft-versus-host disease. AnaptysBio’s antibody pipeline has been developed using its proprietary somatic hypermutation (SHM) platform, which uses in vitro SHM for antibody discovery and is designed to replicate key features of the human immune system to overcome the limitations of competing antibody discovery technologies. AnaptysBio has also developed multiple therapeutic antibodies in an immuno-oncology partnership with TESARO and an inflammation partnership with Celgene, including an anti-PD-1 antagonist antibody (TSR-042) and an anti-TIM-3 antagonist antibody (TSR-022), which are currently under clinical development with TESARO, and an anti-PD-1 checkpoint agonist antibody (CC-90006) currently in the clinic with Celgene. Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: our belief that ANB020’s mechanism has advantages in the treatment of atopic diseases over competing agents, and, specifically, our belief that ANB020’s efficacy in inhibiting IL-33 has the potential to reduce expression of the effector cytokines involved in severe peanut allergy and effectively treat severe peanut allergy; the timing of top-line data from ANB020’s Phase 2a clinical trials for the treatment of severe peanut allergy and moderate-to-severe adult atopic dermatitis; and expectations to seek regulatory clearance during the first half of 2017 to initiate a Phase 2a trial in patients with severe adult eosinophilic asthma, and timing regarding the subsequent release of top-line data from any such trial. Statements including words such as “anticipate,” “believe,” “potential,” “estimate,” “plan,” “will,” “continue,” “expect,” or “future,” and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements are subject to risks and uncertainties that may cause the company’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the company’s ability to advance its product candidates, obtain regulatory approval of and ultimately commercialize its product candidates, the timing and results of preclinical and clinical trials, the company’s ability to fund development activities and achieve development goals, the company’s ability to protect intellectual property and other risks and uncertainties described under the heading “Risk Factors” in documents the company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.  ANAPTYSBIO, INC.CONSOLIDATED BALANCE SHEETS(in thousands, except par value data)   December 31,
2016 December 31,
2015ASSETS    Current assets:    Cash and cash equivalents $ 51,232  $ 51,684 Receivable from collaborative partners   1,225    1,226 Australian tax incentive receivable   4,118    â€” Prepaid expenses and other current assets   1,633    554 Total current assets   58,208    53,464 Property and equipment, net   471    551 Restricted cash   60    60 Deferred financing costs   3,441    2,205 Total assets $ 62,180  $ 56,280 LIABILITIES, CONVERTIBLE PREFERRED STOCK AND
STOCKHOLDERS’ DEFICIT    Current liabilities:    Accounts payable $ 2,278  $ 1,521 Accrued expenses   3,429    2,753 Deferred revenue   â€”    2,942 Income taxes payable   â€”    139 Other current liabilities   1    21 Total current liabilities   5,708    7,376 Notes payable, net of current portion   13,809    4,903 Deferred rent   154    115 Preferred stock warrant liabilities   3,241    1,549 Commitments and contingencies    Series B convertible preferred stock, $0.001 par value, 3,963 shares authorized,
  issued and outstanding at December 31, 2016 and 2015; aggregate
  liquidation preference at December 31, 2016 of $24,991   28,220    28,220 Series C convertible preferred stock, $0.001 par value, 1,887 shares authorized, 1,593  
  shares issued and outstanding at December 31, 2016 and 2015; aggregate
  liquidation preference at December 31, 2016 of $7,246   6,452    6,452 Series C-1 convertible preferred stock, $0.001 par value, 474 shares authorized,
  issued and outstanding at December 31, 2016 and 2015, respectively;
  aggregate liquidation preference at December 31, 2016 of $6,470   2,156    2,156 Series D convertible preferred stock, $0.001 par value, 5,491 shares authorized,
  issued and outstanding at December 31, 2016 and 2015, respectively;
  aggregate liquidation preference at December 31, 2016 of $40,767   40,688    40,688 Stockholders’ deficit:    Common stock, $0.001 par value, 17,214 shares authorized, 2,651 shares and 2,630
  shares issued and outstanding at December 31, 2016 and 2015, respectively   3    3 Additional paid in capital   16,672    15,482 Accumulated deficit   (54,923)   (50,664)Total stockholders’ deficit   (38,248)   (35,179)Total liabilities, convertible preferred stock and stockholders’ deficit $ 62,180  $ 56,280          
 ANAPTYSBIO, INC.CONSOLIDATED STATEMENTS OF OPERATIONS(in thousands, except per share data)   Year Ended December 31,   2016   2015 Collaboration revenue $ 16,684  $ 17,571 Operating expenses:    Research and development   15,419    17,304 General and administrative   4,290    3,589 Total operating expenses   19,709    20,893   Income (loss) from operations   (3,025)   (3,322)Other expense, net    Interest expense   (458)   (460)Interest expense, related parties   â€”    â€” Change in fair value of liability for preferred stock warrants     (756)   (1,277)Other income (expense), net   (20)   (207)Total other expense, net   (1,234)   (1,944)  Income (loss) before income taxes   (4,259)   (5,266)Provision for income taxes   â€”    (139)  Net income (loss)   (4,259)   (5,405)Net income attributed to participating securities   â€”    â€”   Net income (loss) attributed to common stockholders $ (4,259) $ (5,405)Net income (loss) per common share:    Basic and diluted $ (1.62) $ (2.12)Weighted-average number of shares outstanding:    Basic and diluted   2,637    2,551 

Contact:
Monique Allaire
THRUST Investor Relations
617.895.9511
[email protected]

Read more...
AnaptysBio Announces Data from Scientific Collaboration with the Benaroya Research Institute Presented at the AAAAI 2017 Annual Meeting

Data Support Rationale for Development of AnaptysBio’s Anti-IL-33 Antibody, ANB020, for the Treatment of Severe Adult Peanut Allergy
SAN DIEGO, March 04, 2017 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that its scientific collaborators at the Benaroya Research Institute at Virginia Mason (BRI) have presented a translational research study entitled “Role of IL-33 in modulating human allergen-specific pathogenic CD4 T Cell responses,” at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2017 Annual Meeting (Session Number 2604, Presentation Number 208, Saturday March 4, 2017 3:00pm ET, Room B206, Georgia World Congress Center Building B) in Atlanta.
This study, conducted in the laboratory of Dr. Erik Wambre at BRI, assessed the biology of a distinct subset of T cells, called TH2A cells, which are found in elevated frequency in peanut allergic patients when compared to non-allergic individuals. TH2A cells isolated from peanut allergy patients demonstrated increased sensitivity to IL-33 signaling as a result of elevated expression of the IL-33 receptor. Data showed that, upon stimulus with IL-33, TH2A cells express significantly greater levels of effector cytokines IL-4, IL-5, and IL-13, which are believed to be associated with severe peanut allergy. The research concluded that IL-33 is a key checkpoint of allergic responses, and blocking IL-33 has the potential to reduce expression of the effector cytokines involved in severe peanut allergy.These findings provide further scientific support for the development of AnaptysBio’s proprietary anti-IL-33 antibody, known as ANB020, for the treatment of severe adult peanut allergy.  AnaptysBio is currently enrolling severe adult peanut allergy patients in a Phase 2a clinical trial, where top-line data are anticipated during the second half of 2017.About ANB020
ANB020 is a potentially first-in-class antibody that inhibits the activity of IL-33, a pro-inflammatory cytokine that multiple studies have indicated is a central mediator of atopic diseases, including atopic dermatitis, food allergies and asthma. IL-33 directly mediates the release of disease-associated cytokines, which recruit pro-inflammatory cells that mediate atopic disease. Because ANB020 inhibits IL-33 function and acts upstream broadly across the key cell types and cytokines involved in atopy, we believe that its mechanism has advantages in the treatment of atopic diseases over competing agents that block only a subset of the cytokines responsible for atopic diseases. The role of IL-33 signaling in asthma has recently been genetically validated through human studies published in the medical literature. We have cleared a U.S. IND and a U.K. CTA to initiate Phase 2a trials of ANB020 for the treatment of severe adult peanut allergy and moderate-to-severe adult atopic dermatitis, respectively, where we anticipate top-line data from these trials to be announced during the second half of 2017. In addition, we plan to seek regulatory clearance during the first half of 2017 to initiate a Phase 2a trial in patients with severe adult eosinophilic asthma, where we anticipate top-line data from this trial to be announced during the first half of 2018.About AnaptysBio
AnaptysBio is a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation. The company's proprietary anti-inflammatory pipeline includes its anti-IL-33 antibody (ANB020) for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy and severe adult eosinophilic asthma; its anti-IL-36R antibody (ANB019) for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases where immune checkpoint receptors are insufficiently activated and have demonstrated efficacy in an animal model of graft-versus-host disease. AnaptysBio's antibody pipeline has been developed using its proprietary SHM platform, which uses in vitro somatic hypermutation for antibody discovery and is designed to replicate key features of the human immune system to overcome the limitations of competing antibody discovery technologies. AnaptysBio has also developed multiple therapeutic antibodies in partnership with Celgene and TESARO, including an anti-PD-1 antagonist antibody (TSR-042) and an anti-TIM-3 antagonist antibody (TSR-022), which are currently under clinical development with TESARO, and an undisclosed anti-inflammatory antibody currently in the clinic with Celgene.Forward-Looking Statements
This press release contains forward-looking statements about AnaptysBio's expectations, plans, intentions, and strategies, including, but not limited to, statements regarding AnaptysBio 's expectations regarding results or timing of future clinical results or regulatory approvals. Statements including words such as "anticipate," "believe," "estimate," "will," "continue," "expect," or "future," and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The risks and uncertainties include those described in AnaptysBio's documents filed with or furnished to the Securities and Exchange Commission. All forward-looking statements in this press release are based on information available to AnaptysBio as of the date hereof. AnaptysBio assumes no obligation to update these forward-looking statements.
Contact:
Monique Allaire
THRUST Investor Relations
617.895.9511
[email protected]

Read more...

Ratios

vs
industry
vs
history
PB Ratio 5.00
ANAB's PB Ratio is ranked lower than
54% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. ANAB: 5.00 )
Ranked among companies with meaningful PB Ratio only.
ANAB' s PB Ratio Range Over the Past 10 Years
Min: 4.13  Med: 4.6 Max: 5.23
Current: 5
4.13
5.23
PS Ratio 30.53
ANAB's PS Ratio is ranked lower than
69% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. ANAB: 30.53 )
Ranked among companies with meaningful PS Ratio only.
ANAB' s PS Ratio Range Over the Past 10 Years
Min: 25.17  Med: 28 Max: 31.9
Current: 30.53
25.17
31.9
EV-to-EBIT -32.96
ANAB's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. ANAB: -32.96 )
Ranked among companies with meaningful EV-to-EBIT only.
ANAB' s EV-to-EBIT Range Over the Past 10 Years
Min: -34.69  Med: -20.8 Max: -18.1
Current: -32.96
-34.69
-18.1
EV-to-EBITDA -33.46
ANAB's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. ANAB: -33.46 )
Ranked among companies with meaningful EV-to-EBITDA only.
ANAB' s EV-to-EBITDA Range Over the Past 10 Years
Min: -35.25  Med: -21.2 Max: -18.4
Current: -33.46
-35.25
-18.4
Current Ratio 13.56
ANAB's Current Ratio is ranked higher than
87% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. ANAB: 13.56 )
Ranked among companies with meaningful Current Ratio only.
ANAB' s Current Ratio Range Over the Past 10 Years
Min: 2.01  Med: 6.94 Max: 13.56
Current: 13.56
2.01
13.56
Quick Ratio 13.56
ANAB's Quick Ratio is ranked higher than
87% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. ANAB: 13.56 )
Ranked among companies with meaningful Quick Ratio only.
ANAB' s Quick Ratio Range Over the Past 10 Years
Min: 2.01  Med: 6.94 Max: 13.56
Current: 13.56
2.01
13.56
Days Sales Outstanding 108.62
ANAB's Days Sales Outstanding is ranked lower than
73% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. ANAB: 108.62 )
Ranked among companies with meaningful Days Sales Outstanding only.
ANAB' s Days Sales Outstanding Range Over the Past 10 Years
Min: 25.47  Med: 33.53 Max: 116.89
Current: 108.62
25.47
116.89

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 6.69
ANAB's Price-to-Net-Cash is ranked higher than
59% of the 530 Companies
in the Global Biotechnology industry.

( Industry Median: 7.61 vs. ANAB: 6.69 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ANAB' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 6.45  Med: 6.82 Max: 6.99
Current: 6.69
6.45
6.99
Price-to-Net-Current-Asset-Value 6.19
ANAB's Price-to-Net-Current-Asset-Value is ranked higher than
59% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. ANAB: 6.19 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ANAB' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 5.96  Med: 6.31 Max: 6.47
Current: 6.19
5.96
6.47
Price-to-Tangible-Book 5.01
ANAB's Price-to-Tangible-Book is ranked higher than
54% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. ANAB: 5.01 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ANAB' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4.82  Med: 5.1 Max: 5.23
Current: 5.01
4.82
5.23
Price-to-Median-PS-Value 1.09
ANAB's Price-to-Median-PS-Value is ranked lower than
51% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. ANAB: 1.09 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ANAB' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 1.05  Med: 1.11 Max: 1.14
Current: 1.09
1.05
1.14
Earnings Yield (Greenblatt) % -3.07
ANAB's Earnings Yield (Greenblatt) % is ranked higher than
62% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. ANAB: -3.07 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ANAB' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -5.5  Med: -4.8 Max: -2.89
Current: -3.07
-5.5
-2.89

More Statistics

Revenue (TTM) (Mil) $16.68
EPS (TTM) $ -0.89
Short Percentage of Float3.78%
52-Week Range $15.17 - 29.96
Shares Outstanding (Mil)20.27

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 9 6 25
EPS ($) -1.32 -2.87 -3.55
EPS without NRI ($) -1.32 -2.87 -3.55
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ANAB

Headlines

Articles On GuruFocus.com
AnaptysBio to Participate in Upcoming Investor Conferences Jun 01 2017 
AnaptysBio Announces First Quarter 2017 Financial Results and Provides Pipeline Update May 11 2017 
AnaptysBio Announces First-In-Human Dosing of ANB019 Apr 06 2017 
AnaptysBio Announces 2016 Operating Results and Pipeline Progress Mar 08 2017 
AnaptysBio Announces Data from Scientific Collaboration with the Benaroya Research Institute Present Mar 04 2017 

More From Other Websites
ETFs with exposure to AnaptysBio, Inc. : July 14, 2017 Jul 14 2017
AnaptysBio, Inc. breached its 50 day moving average in a Bullish Manner : ANAB-US : July 13, 2017 Jul 13 2017
AnaptysBio, Inc. – Value Analysis (NASDAQ:ANAB) : June 28, 2017 Jun 28 2017
AnaptysBio, Inc. breached its 50 day moving average in a Bullish Manner : ANAB-US : June 27, 2017 Jun 27 2017
Why AnaptysBio (ANAB) Could Be Positioned for a Slump Jun 09 2017
AnaptysBio to Participate in Upcoming Investor Conferences Jun 01 2017
AnaptysBio, Inc. breached its 50 day moving average in a Bearish Manner : ANAB-US : May 29, 2017 May 29 2017
AnaptysBio Announces First Quarter 2017 Financial Results and Provides Pipeline Update May 11 2017
AnaptysBio, Inc. – Value Analysis (NASDAQ:ANAB) : April 20, 2017 Apr 20 2017
AnaptysBio, Inc. breached its 50 day moving average in a Bearish Manner : ANAB-US : April 19, 2017 Apr 19 2017
ETFs with exposure to AnaptysBio, Inc. : April 5, 2017 Apr 05 2017
Will Snap, MuleSoft IPOs Kick Up A Stampede Of Tech Unicorns? Mar 30 2017
AnaptysBio, Inc. :ANAB-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Mar 20 2017
AnaptysBio, Inc. :ANAB-US: Earnings Analysis: 2016 By the Numbers : March 16, 2017 Mar 16 2017
Biotech IPOs Slow As Trump-Sown Uncertainty Rattles Nerves On Wall Street Feb 14 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}